Eisai models ¥300 billion in potential Leqembi sales for fiscal year 2028
BioArctic announced that its long-term development and commercialization partner, Eisai, has presented an updated financial simulation outlining the growth trajectory for their co-developed Alzheimer’s disease treatment, Leqembi (lecanemab).










